Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 32Triple Negative Breast Neoplasms 26Carcinoma, Transitional Cell 9Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 8Urinary Bladder Neoplasms 7Lung Neoplasms 4Endometrial Neoplasms 3Brain Neoplasms 3Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

pembrolizumab 6Injections 6senaparib 4toripalimab 3tislelizumab 3Bevacizumab 3sintilimab 2Technetium 2Specimen Handling 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Carboplatin 2Blood Specimen Collection 2zimberelimab 1tumor-cells apoptosis factor, human 1tazemetostat 1spartalizumab 1sacituzumab govitecan 1rucaparib 1osimertinib 1olaparib 1etoposide phosphate 1enzalutamide 1envafolimab 1cemiplimab 1cedazuridine 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Ultrasonography, Doppler 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × sacituzumab govitecan × 1 year × Clear all
NCT05119907 2025-11-17

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Gilead Sciences

Phase 2 Active not recruiting
53 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡